Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

Slides:

Advertisements

Similar presentations

Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy Yitzhak Katz, MD, Nelly Rajuan, MSc, Michael R. Goldberg,

Advertisements

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Does BCG vaccination protect against childhood asthma

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Allergen immunotherapy: A practice parameter third update

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study Eli O. Meltzer, MD, Paul.

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis Alain Didier, MD,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults Peter S. Creticos, MD, Jennifer Maloney,

Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison Danilo Di.

Network Meta-analysis Shows Commercialized Subcutaneous and Sublingual Grass Products Have Comparable Efficacy Harold Nelson, MD, Shannon Cartier, MSc,

Is 9 more than 2 also in allergic airway inflammation?

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: Patterns of care, resource use, and costs Cheryl S. Hankin, PhD, Linda.

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy.

Response to sublingual immunotherapy with grass pollen extract: Monotherapy versus combination in a multiallergen extract Sheila M. Amar, MD, Ronald.

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Hendrik Nolte, MD, PhD, David I

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Reply Journal of Allergy and Clinical Immunology

Impact of Adverse Event Solicitation on the Safety Profile of SQ House Dust Mite Sublingual Immunotherapy Tablet Hendrik Nolte, MD, PhD, David I. Bernstein,

Peter M. Wolfgram, MD, David B. Allen, MD

Does BCG vaccination protect against childhood asthma

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Atopic dermatitis: A practice parameter update 2012

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Sequential Treatment Initiation with Timothy Grass and Ragweed Sublingual Immunotherapy Tablets Followed by Simultaneous Treatment Is Well Tolerated

Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial Hendrik.

Allergen-specific immunotherapy with recombinant grass pollen allergens Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,

Daphne Koinis-Mitchell, PhD, Timothy Craig, DO, Cynthia A

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

What is an “eosinophilic phenotype” of asthma?

Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis Stephen R. Durham,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Autophagy: Nobel Prize 2016 and allergy and asthma research

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

House dust mite sublingual immunotherapy: Results of a US trial

Impact of Adverse Event Solicitation on the Safety Profile of SQ House Dust Mite Sublingual Immunotherapy Tablet Hendrik Nolte, MD, PhD, David I. Bernstein,

Local allergic rhinitis: Allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen Carmen Rondón, MD, PhD, Natalia.

Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years Ronald Dahl, MD,

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet Stephen.

Piotr Kuna, MD, Jadwiga Kaczmarek, MD, Maciej Kupczyk, MD

Reply Journal of Allergy and Clinical Immunology

Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis Philippe-Jean Bousquet, MD, Christophe Combescure, PhD,

Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite–induced allergic.

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Macrolide antibiotics and asthma treatment

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

Effect of grass sublingual tablet immunotherapy is similar in children and adults: A Bayesian approach to design pediatric sublingual immunotherapy trials

News Beyond Our Pages Journal of Allergy and Clinical Immunology

Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen Piyush Patel, MD, Tom Holdich, MBBS,

Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: A systematic review and indirect comparison Janine Dretzke, MSc, Angela Meadows,

An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment Eli O. Meltzer, MD, Robert B. Berkowitz,

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Presentation transcript:

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham, MD, Peter S. Creticos, MD, Harold S. Nelson, MD, Ziliang Li, PhD, Amarjot Kaur, PhD, Eli O. Meltzer, MD, Hendrik Nolte, MD, PhD Journal of Allergy and Clinical Immunology Volume 138, Issue 4, Pages 1081-1088.e4 (October 2016) DOI: 10.1016/j.jaci.2016.04.061 Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 TNSS improvements with timothy grass and ragweed SLIT-tablets relative to placebo for SAR. *Calculated as follows: ([Active treatment − Placebo]/Placebo) × 100%. †Relative percentage improvement in rhinoconjunctivitis daily rescue medication score ranged from 27% to 38% in the trials. ‡Relative percentage improvement in rhinoconjunctivitis daily rescue medication score was 38% and 46% in the 2 trials. FE, Fixed effects. Journal of Allergy and Clinical Immunology 2016 138, 1081-1088.e4DOI: (10.1016/j.jaci.2016.04.061) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 TNSS improvements with montelukast relative to placebo for SAR and PAR. *Calculated as follows: ([Active treatment − Placebo]/Placebo) × 100%. FE, Fixed effects. Journal of Allergy and Clinical Immunology 2016 138, 1081-1088.e4DOI: (10.1016/j.jaci.2016.04.061) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 TNSS improvements with desloratadine relative to placebo for SAR and PAR. *Calculated as follows: ([Active treatment − Placebo]/Placebo) × 100%. †Trial allowed decongestant use. FE, Fixed effects. Journal of Allergy and Clinical Immunology 2016 138, 1081-1088.e4DOI: (10.1016/j.jaci.2016.04.061) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 TNSS improvements with MFNS relative to placebo for SAR and PAR. *Calculated as follows: ([Active treatment − Placebo]/Placebo) × 100%. †Trial allowed antihistamine use. FE, Fixed effects. Journal of Allergy and Clinical Immunology 2016 138, 1081-1088.e4DOI: (10.1016/j.jaci.2016.04.061) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 5 TNSS improvements with HDM SLIT-tablets relative to placebo for PAR. *Calculated as follows: ([Active treatment − Placebo]/Placebo) × 100%. †Relative percentage improvement in rhinitis daily rescue medication score in the 2 trials was 18% and 21%. FE, Fixed effects. Journal of Allergy and Clinical Immunology 2016 138, 1081-1088.e4DOI: (10.1016/j.jaci.2016.04.061) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions